Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

RyCarma Therapeutics named Adam Rosenberg, former CEO of Aliada Therapeutics and Sionna Therapeutics, as its CEO. It also hired Jonathan Alspaugh as president and chief strategy officer and Sanjay ...

The stock's fall snapped a two-day winning streak.

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.